2nd World Congress on

Diabetes & Metabolism

Diabetes & Metabolism 2022

Theme: Exploring New Insights and Preventive Measures for Diabetes & Metabolism

We are delighted to announce the upcoming “2nd World Congress on Diabetes & Metabolism” scheduled to be held on September 23-24, 2022 in Osaka, Japan. The theme of the Conference is “Exploring New Insights and Preventive Measures for Diabetes & Metabolism”. Diabetes & Metabolism 2022 is a global platform to discuss and learn about Diabetes & Endocrinology as well as its related areas of healthcare which include overview, prevalence, trends and disparities, causes and its associated health problems and co-dependent relationship between Diabetes & Metabolism . 
 
Diabetes & Metabolism 2022 will bring together world-class Directors, Professors, Scientists and Researchers to discuss the multidisciplinary field with research and interests covering all aspects of recent Diabetes Healthcare, Metabolism & Obesity. This Conference shall include prompt keynote presentations, special sessions, workshops, symposiums, oral talks, poster presentations and exhibitions.

 

Track 1: Diabetes and Metabolism
 
The metabolism of people with diabetes differs to the metabolism of people without it. In type 2 diabetes, the effectiveness of insulin is reduced and in type 1 diabetes, insulin levels in the body are very low. For this reason, type 1 diabetics require insulin delivery from other methods. Insulin resistance, most common in pre-diabetes. metabolic syndrome and type 2 diabetes, impairs the body’s ability to metabolise glucose. Consequently blood sugars become elevated, weight gain is more likely and the resistance to insulin becomes greater. Metabolism refers to the chemical reactions that take place inside the cells of living organisms which are essential for life. For the purposes of this guide, metabolism refers to the processes that occur in the body once food is eaten.
 
Track 2: Diabetes & Endocrinology
 
Endocrine disorders involve the body’s over- or under-production of certain hormones, while metabolic disorders affect the body’s ability to process certain nutrients and vitamins. Endocrine disorders include hypothyroidism, congenital adrenal hyperplasia, diseases of the parathyroid gland, diabetes mellitus, diseases of the adrenal glands (including Cushing’s syndrome and Addison’s disease), and ovarian dysfunction (including polycystic ovary syndrome), among others. Behavioural endocrinology is the study of hormonal processes and neuroendocrine systems that influence or regulate behaviour. Endocrinology includes the wide area that not only affects our endocrine system, but also has effects on skin which shows indirectly involvement of dermatology.
 
Track 3: Diabetes Mellitus
 
Diabetes mellitus is a disease that prevents your body from properly using the energy from the food you eat. Diabetes occurs in one of the following situations: The pancreas (an organ behind your stomach) produces little insulin or no insulin at all. Insulin is a naturally occurring hormone, produced by the beta cells of the pancreas, which helps the body use sugar for energy. To better understand diabetes, it helps to know more about how the body uses food for energy (a process called metabolism). Your body is made up of millions of cells. To make energy, the cells need food in a very simple form. When you eat or drink, much of your food is broken down into a simple sugar called glucose. Glucose provides the energy your body needs for daily activities. The blood vessels and blood are the highways that transport sugar from where it is either taken in (the stomach) or manufactured (in the liver) to the cells where it is used (muscles) or where it is stored (fat). Sugar isn't able to go into the cells by itself. The pancreas releases insulin into the blood, which serves as the helper, or the "key," that lets sugar into the cells for use as energy.
 
Track 4: Type 1 and Type 2 Diabetes, Complications and Treatment
 
The body’s immune system is responsible for fighting off foreign invaders, like harmful viruses and bacteria. In people with type 1 diabetes, the immune system mistakes the body’s own healthy cells for foreign invaders. The immune system attacks and destroys the insulin-producing beta cells in the pancreas. After these beta cells are destroyed, the body is unable to produce insulin. People with type 2 diabetes have insulin resistance. The body still produces insulin, but it’s unable to use it effectively. Researchers aren’t sure why some people become insulin resistant and others don’t, but several lifestyle factors may contribute, including excess weight and inactivity. Other genetic and environmental factors may also contribute. When you develop type 2 diabetes, your pancreas will try to compensate by producing more insulin. Because your body is unable to effectively use insulin, glucose will accumulate in your bloodstream.
 
Track 5: Obesity and Metabolism
 
Obesity is increasing at unprecedented levels globally, and the overall impact of obesity on the various organ systems of the body is only beginning to be fully appreciated. Because of the myriad of direct and indirect effects of obesity causing dysfunction of multiple tissues and organs, it is likely that there will be heterogeneity in the presentation of obesity effects in any given population. Taken together, these realities make it increasingly difficult to understand the complex interplay between obesity effects on different organs, including the brain. The focus of this review is to provide a comprehensive view of metabolic disturbances present in obesity, their direct and indirect effects on the different organ systems of the body, and to discuss the interaction of these effects in the context of brain aging and the development of neurodegenerative diseases.
 
Track 6: Gestational Diabetes-Treatment and Care
 
Approximately 90% of diabetes cases in pregnant women are considered gestational diabetes mellitus (GDM). It is well known that uncontrolled glucose results in poor pregnancy outcomes in both the mother and fetus. Worldwide there are many guidelines with recommendations for appropriate management strategies for GDM once lifestyle modifications have been instituted and failed to achieve control. The efficacy and particularly the safety of other treatment modalities for GDM has been the source of much debate in recent years. Studies that have demonstrated the safety and efficacy of both glyburide and metformin in the management of patients with GDM will be reviewed. There is a lack of evidence with other oral and injectable non-insulin agents to control blood glucose in GDM. The role of insulin will be discussed, with emphasis on insulin analogs. Ideal patient characteristics for each treatment modality will be reviewed. In addition, recommendations for postpartum screening of patients will be described as well as recommendations for use of agents to manage subsequent type 2 diabetes in patients who are breastfeeding.
 
Track 7: Diabetes Diet, Nutrition- Eating, & Physical Activity
 
A diabetes diet simply means eating the healthiest foods in moderate amounts and sticking to regular mealtimes. A diabetes diet is a healthy-eating plan that's naturally rich in nutrients and low in fat and calories. Key elements are fruits, vegetables and whole grains. In fact, a diabetes diet is the best eating plan for most everyone. Along with healthy eating, physical activity is important. Be as active as possible in as many different ways as possible. Aim to do at least 30 minutes of moderate intensity physical activity on most, if not all days of the week. A regular half-hour of physical activity can help to:
 
Lower your blood glucose levels
Lower your cholesterol
Lower your blood pressure
Reduce stress and anxiety
Improve your mood and self-esteem
Improve the quality of your sleep
Increase muscle and bone strength.
Diabetes Therapeutics and Diagnostics
 
The incidence rate of diabetes is exceptionally high across the globe, fueled by reducing physical activities and unhealthy diet. According to IMARC’s report, compared to Type-1 diabetes, Type-2 diabetes represents the more prevalent type, accounting for the majority of all diagnosed diabetes cases. Urban areas dominate rural areas in the number of diabetes patients and females presently account for the majority of the total diabetes patients. Despite the general down climate of the economy and healthcare, there has been great progress in the advancement of diabetes knowledge, treatment and prevention in recent years. This progress continues of a daily basis, with scientific advances being announced at an exponential rate. New therapeutic products are being introduced regularly and the pipeline is now full of new diabetes therapeutics in development.
 
Track 8: Paediatric Diabetes and Treatment
 
Diabetes mellitus involves absence of insulin secretion (type 1) or peripheral insulin resistance (type 2), causing hyperglycemia. Early symptoms are related to hyperglycemia and include polydipsia, polyphagia, polyuria, and weight loss. Diagnosis is by measuring plasma glucose levels. Treatment depends on type but includes drugs that reduce blood glucose levels, diet, and exercise.  The types of diabetes mellitus (diabetes) in children are similar to those in adults, but psychosocial problems are different and can complicate treatment. Type 1 diabetes is the most common type in children, accounting for two thirds of new cases in children of all ethnic groups. It is one of the most common chronic childhood diseases, occurring in 1 in 350 children by age 18; the incidence has recently been increasing, particularly in children < 5 years. Although type 1 can occur at any age, it typically manifests between age 4 years and 6 years or between 10 years and 14 years. Type 2 diabetes, once rare in children, has been increasing in frequency in parallel with the increase in childhood obesity (see obesity in children). It typically manifests after puberty, with the highest rate between age 15 years and 19 years (see obesity in adolescents).
 
Track 9: Diabetes Wound Care and Management
 
Minor wounds, cuts, and burns are an unfortunate but unavoidable part of life. However, for people with diabetes, these injuries can lead to serious health issues. Many people with diabetes develop wounds that are slow to heal, do not heal well, or never heal. Sometimes, an infection might develop. An infection can spread to tissue and bone near the wound or more distant areas of the body. In some cases, and without emergency care, an infection can be life-threatening or may even be fatal. Even when an infection does not develop in a wound, slow healing can adversely affect a person’s overall health and quality of life. Cuts or injuries on the feet or legs can make walking difficult or exercise painful. It is essential that people who have diabetes keep their blood sugar levels under control to reduce the risk of slow-healing wounds and complications, including foot ulcers. According to some reports, foot ulcers will develop in about 1 in 4 people with diabetes. Foot ulcers are painful sores that can ultimately lead to foot amputation.
 
Track 10: Diabetes Increases Risk of Sepsis - Diabetes in Control
 
Sepsis develops when an infection surpasses local tissue containment. A series of dysregulated physiological responses are generated, leading to organ dysfunction and a 10% mortality risk. When patients with sepsis demonstrate elevated serum lactates and require vasopressor therapy to maintain adequate blood pressure in the absence of hypovolemia, they are in septic shock with an in-hospital mortality rate >40%. With improvements in intensive care treatment strategies, overall sepsis mortality has diminished to ~20% at 30 days; however, mortality continues to steadily climb after recovery from the acute event. Traditionally, it was thought that the complex interplay between inflammatory and anti-inflammatory responses led to sepsis-induced organ dysfunction and mortality. However, a closer examination of those who die long after sepsis subsides reveals that many initial survivors succumb to recurrent, nosocomial, and secondary infections.
 
Track 11: Advanced Technologies for Treatment of Diabetes
 
Blood glucose (blood sugar) monitoring is the main tool you have to check your diabetes control. This check tells you your blood glucose level at any one time. The artificial pancreas bridges the gap between two pieces of diabetes technology that already exist: the insulin pump and the continuous glucose monitor (CGM). Relatively, a large percentage of world population is affected by diabetes mellitus, out of which approximately 5-10% with type 1 diabetes while the remaining 90% with type 2. Insulin administration is essential for type 1 patients while it is required at later stage by the patients of type 2. Current insulin delivery systems are available as transdermal injections which may be considered as invasive. Several non-invasive approaches for insulin delivery are being pursued by pharmaceutical companies to reduce the pain, and hypoglycemic incidences associated with injections in order to improve patient compliance.
 
Insulin pumps and insulin infusion systems
Insulin secretion in vitro and exocytosis
Insulin Pens and novel Insulin delivery techniques
Acupuncture for diabetic complications
Bariatric surgery versus intensive medical and conventional therapy
Artificial pancreas
Glucose sensors (invasive and non-invasive)
Implantable pumps and sensors
Closed-loop system and algorithm
Informatics in the service of medicine; telemedicine, software and other technologies
New insulin delivery systems: Inhaled, transdermal, and implanted devices
Blood glucose monitoring: Glucose pumps and sensors
 
Track 12: Diabetic Retinopathy
 
Diabetic retinopathy is the most common form of diabetic eye disease. Diabetic retinopathy usually only affects people who have had diabetes (diagnosed or undiagnosed) for a significant number of years. Retinopathy can affect all diabetics and becomes particularly dangerous, increasing the risk of blindness, if it is left untreated. The risk of developing diabetic retinopathy is known to increase with age as well with less well controlled blood sugar and blood pressure level. Diabetic retinopathy occurs when changes in blood glucose levels cause changes in retinal blood vessels. In some cases, these vessels will swell up (macular oedema) and leak fluid into the rear of the eye. In other cases, abnormal blood vessels will grow on the surface of the retina. Unless treated, diabetic retinopathy can gradually become more serious and progress from ‘background retinopathy’ to seriously affecting vision and can lead to blindness.
 
Diabetic retinopathy includes 3 different types :
 
Background retinopathy
Diabetic maculopathy
Proliferative retinopathy  
Diabetic Nephropathy and Urine
 
Diabetic nephropathy is common. One in 4 women and one in 5 men with type 2 diabetes develops diabetic nephropathy. It is even more common in type 1 diabetes. Diabetic nephropathy usually has no symptoms early on. You can’t tell that there is protein in your urine – it’s something that is detected with a urine test. It can take many years for the kidney damage to progress. Symptoms usually only appear when kidney damage has deteriorated significantly. Even then, the symptoms tend to be vague.
 
If the kidney damage becomes severe, you may notice:
 
Weight loss
A poor appetite or feeling sick
Swollen ankles and feet (due to retaining fluid)
Puffiness around the eyes
Dry, Itchy skin
Muscle cramps
Needing to pass urine more often
Feeling tired
Having difficulty concentrating
 
Track 13: Advancement of New Drug/Biomarker Discovery for Treatment of Diabetes
 
Biomarkers are essential for the identification of high risk children as well as monitoring of prevention outcomes for type 1 diabetes (T1D).  As a prognostic biomarker for progression of diabetic nephropathy, albuminuria fails in terms of sensitivity and specificity. Better urinary or plasma biomarkers are needed that can predict which diabetic patients are at highest risk for progression. Bhensdadia et al. report proteomic investigations that identified urinary haptoglobin as a potential prognostic biomarker for progressive diabetic nephropathy. Although as a single marker urinary haptoglobin adds little to albuminuria, together the two appear to provide better diagnostic accuracy than albuminuria alone. Excess adiposity is the most important risk factor for the development of insulin resistance and type 2 diabetes (1). However, mechanisms whereby body fat induces insulin resistance in distant tissues are not well understood. Recent evidence indicates that obesity may be an inflammatory markers.
 
Prognostic biomarkers
Diabetic nephropathy biomarkers
Diabetes: Clinical trials and new biomarkers under development
Pharmacotherapy in treatment of diabetes
Molecular markers for both metabolic syndrome and hypoglycemia responses
Inflammatory markers: Type 2 diabetes
New drug treatments and devices for diabetes: current research

Market Analysis

The global diabetes market is driven by components such as increasing incidence of diabetes, technological advancements, and innovative product launches. Enlarge assumption of begin diabetes management solutions in government policies, and rising medical tourism are some of the major factors serving to market growth. Furthermore, rising government initiatives to spread awareness about diabetes and increasing R&D expenditure of major players are the factors expected to boost market growth. The global diabetes implement market size is awaiting to reach USD 41.6 billion by 2027, registering a CAGR of 7.8% over the divine period, according to a new report.

Significance and Scope

Meeting on Diabetes is concentrating on different points, which will focus on a higher number of gatherings of people. This gathering will give a stage to communicate the new headways in the field of diabetes and endocrinology foundation. Diabetes meeting will unite scholarly and modern callings, prompting a spic and span understanding. We realize it is less demanding to comprehend the examination from the scientist and more accommodating as opposed to understanding about diabetes.

World Analysis

As indicated by the International Diabetes conference insights, currently every seven seconds someone is reckoned to die from diabetes or by its complications. 50% of the deaths are happening mostly under the age of 60 years. Diabetes preponderance has risen more rapidly in developing countries. By the year 2045, diabetes is expected to increase further to 9.9% globally. This counts a population of 424.9 million people with diabetes in 2017 will extend to 48% which will be around 628.6 million people. Pragmatically 50% of the deaths from Hyperglycaemia happen before the age of 70 years.

Societies Associated with Diabetes Care

  • Endocrine Society Australia, Australia
  • American Diabetes Association, Virginia
  • European Society of Endocrinology, UK
  • British Society for Neuroendocrinology, London
  • International Neuroendocrine Federation, Canada
  • Association of British Clinical Diabetologist, UK
  • International Society of Endocrinology, Switzerland
  • Panhellenic Association of Endocrinologists, Greece
  • Spanish Society of Endocrinology and Nutrition, Spain
  • International Society of Psychoneuroendocrinology, Italy
  • The American Association of Clinical Endocrinology, Florida
  • British Society for Paediatric Endocrinology and Diabetes, UK
  • British Association of Endocrine and Thyroid Surgeons, London
  • Royal Society of Medicine Endocrinology and Diabetes Section, London
  • Egyptian Association of  Endocrinology, Diabetes And Atherosclerosis, Egypt

Global Universities Associated with Diabetes and Endocrinology

America Region

  • University of Alabama, USA
  • Mayo Medical School, USA
  • University of Arizona, USA
  • University of Arizona, USA
  • University of Arkansas, USA
  • California Northstate University, USA
  • Charles R. Drew University of Medicine and Science, USA
  • Keck School of Medicine of University of Southern California, USA
  • Loma Linda University, USA
  • Stanford University, USA
  • University of California, USA
  • George Washington University, USA
  • Florida International University, USA
  • University of Florida, USA
  • University of Calgary, Canada
  • University of Western Ontario, Canada
  • University of Waterloo, Canada
  • University of Montreal, Canada
  • McMaster University, Canada
  • University of Alberta, Canada
  • University of Sao Paulo, Brazil
  • Federal University of Rio De Janeiro, Brazil
  • Sao Paulo State University, Brazil
  • Federal University of Sao Paulo, Brazil
  • Federal University of Rio Grande Do Sul, Brazil

Asia Region

  • The University of Tokyo, Japan
  • National University of Singapore, Singapore
  • Kyoto University, Japan
  • University of Hong Kong, Hong Kong
  • Peking University, China
  • Seoul National University, South Korea
  • National Taiwan University, Taiwan
  • Osaka University, Japan
  • Nanyang Technological University, Singapore
  • Sungkyunkwan University, South Korea
  • Universiti Malaya, Malaysia
  • Indian Institute of Science, India
  • Universiti Kebangsaan Malaysia, Malaysia
  • University of Indonesia, Indonesia
  • Indian Institute of Technology Bombay, India
  • The Hong Kong University of Science and Technology (HKUST), Hong Kong

Middle East Region

  • Arabian Gulf University, Bahrain
  • Faculty of Medicine Zagazig University, Egypt
  • Benha University, Egypt
  • Fayoum Faculty of Medicine, Egypt
  • Bushehr University of Medical Sciences, Iran
  • Dezful University of Medical Sciences, Iran
  • Fasa Faculty of Medical Sciences, Iran
  • University of Kerabala, Iraq
  • University of Duhok, Iraq
  • Thi Qar University, Iraq
  • Minia Medical School, Egypt
  • Royal College of Surgeons in Ireland, Bahrain
  • Fatemiye University of Medical Sciences, Iran
  • Assiut Faculty of Medicine, Egypt
  • Suez Canal Faculty of Medicine, Egypt

Europe Region

  • LMU Munich, Germany
  • Technical University of Munich, Germany
  • University of Leuven, Belgium
  • University of Amsterdam, Netherlands
  • Humboldt University of Berlin, Germany
  • Leiden University, Netherlands
  • Utrecht University, Netherlands
  • Erasmus University Rotterdam, Netherlands
  • RWTH Aachen University, Germany
  • University of Groningen, Netherlands
  • University of Copenhagen, Denmark
  • University of Barcelona, Spain
  • University of Helsinki, Finland

Global Diabetes-endocrinology Research Centers

  • Joslin Diabetes Center, USA
  • Diabetes Research Institute Foundation, USA
  • UCSF Diabetes Center, USA
  • Mayo Clinic, USA
  • Vanderbilt Diabetes Center, USA
  • Euradia, England
  • Dyna Health, Finland
  • Oxford Centre for Diabetes, Endocrinology and Metabolism, England
  • Lundberg Laboratory for Diabetes Research, Sweden
  • German Center for Diabetes Research, Sweden
  • Diabetes Complications Research Centre, Ireland
  • Dubai Diabetes Center, UAE
  • Diabetes Research Center, Japan
  • Imperial College London Diabetes Center, UAE
  • Hong Kong Institute of Diabetes and Obesity, China
  • Korea University Medical Center, South Korea
  • Tel Aviv Sourasky Medical Center, Israel
  • Sheba Medical Center, Israel
  • RAK Diabetes Center, UAE

Global Diabetes-Endocrinology Medicals/Hospitals

America Region

  • Cleveland Clinic, USA
  • Massachusetts General Hospital, USA
  • Johns Hopkins Hospital, USA
  • UCSF Medical Center, USA
  • New York-Presbyterian University Hospital of Columbia and Cornell, Canada
  • Yale-New Haven Hospital, USA
  • Northwestern Memorial Hospital, USA
  • UCLA Medical Center, Canada
  • University of Washington Medical Center, USA
  • Hospitals of the University of Pennsylvania-Penn Presbyterian, USA
  • Brigham and Women’s Hospital, USA
  • Florida Hospital Orlando, USA
  • Cedars-Sinai Medical Center, Canada
  • Barnes-Jewish Hospital/Washington University, USA
  • Beaumont Hospital, USA
  • Mount Sinai Hospital, USA
  • Froedtert Hospital and the Medical College of Wisconsin, USA
  • Lancaster General Hospital, USA
  • University of Kansas Hospital, USA
  • Hospital Municipal Mendez, Argentina

Asian Region

  • Royal Prince Alfred Hospital, Australia
  • Royal Melbourne Hospital, Australia
  • Waikato Hospital, New Zealand
  • Faculty of Medicine Siriraj Hospital, Thailand
  • Prince Court Medical Centre, Malaysia
  • Fortis C-DOC Hospital, India
  • S. L Raheja Hospital, India
  • Apollo Hospitals, India
  • Indraprastha Apollo Hospital, India
  • Manipal Hospital, India
  • Tongji Hospital, China
  • Peking University People's Hospital, China
  • Peking University First Hospital, China
  • Bumrungrad International Hospital, Thailand
  • Bangkok Hospital Medical Center, Thailand
  • Gleneagles Hospital, Singapore

Middle East Region

  • King Faisal Specialist Hospital & Research Centre, Saudi Arabia
  • Riyadh Military Hospital, Saudi Arabia
  • Kbb Istanbul, Turkey
  • Ankara Saglik Müdürlügü, Turkey
  • Medicana Hospital Group, Turkey
  • American Hospital, UAE
  • Bezmi Alem Valide Sultan Vakif Gureba E A Hastanesi, Turkey
  • Hille Yaffe Medical Center, Israel
  • Erfan Hospital, Saudi Arabia
  • Ankara Numone Hospital, Turkey
  • Zulekha Hospital, UAE
  • Denizli Devlet Hastanesi, Turkey
  • King Fahad Medical Ci, Saudi Arabia

Europe Region

  • Swiss Prevention Clinic, Switzerland
  • Klinik Pyramide Am See, Switzerland
  • Health Centre, Switzerland
  • Clinique Générale-Beaulieu, Switzerland
  • Klinik Im Park, Switzerland
  • Klinik Hirslanden, Switzerland
  • Klinik Beau-Site, Switzerland
  • Hirslanden Clinique La Colline, Switzerland
  • Salem-Spital, Switzerland
  • Hirslanden Klinik, Switzerland
  • w. Goethe university hospital, Germany

Global Diabetes-Endocrinology Companies

  • Abbott Diabetes Care, USA
  • Accu-Chek, USA
  • Arkray USA, USA
  • Bayer, USA
  • LifeScan, USA
  • Animas, USA
  • Asante Solutions, USA
  • Abbot Laboratories, USA
  • Amylin Pharmaceuticals, USA
  • Aventis Pharmaceuticals, USA
  • Becton-Dickinson, USA
  • Bristol-Myers Squibb, USA
  • Novo Nordisk, USA
  • Pfizer, USA
  • SmithKline Beecham, USA
  • Takeda Pharmaceuticals, USA
  • Valeant, USA
  • Euradia, UK
  • MedTech Europe, Belgium
  • Cellnovo, France
  • Novo-Nordisk, Denmark
  • Acino, France
  • Thio Matrix -Austria
  • Biocrates, Austria
  • Diabetes and Metabolism
  • Diabetes & Endocrinology
  • Diabetes Mellitus
  • Type 1 and Type 2 Diabetes, Complications and Treatment
  • Obesity and Metabolism
  • Gestational Diabetes-Treatment and Care
  • Diabetes Diet, Nutrition- Eating, & Physical Activity
  • Paediatric Diabetes and Treatment
  • Diabetes Wound Care and Management
  • Diabetes Increases Risk of Sepsis - Diabetes in Control
  • Advanced Technologies for Treatment of Diabetes
  • Diabetic Retinopathy
  • Advancement of New Drug/Biomarker Discovery for Treatment of Diabetes